{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T14:24:28Z","timestamp":1771079068930,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/02259"],"award-info":[{"award-number":["PI17\/02259"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Schizophrenia is a chronic mental condition presenting a wide range of symptoms. Although it has a low prevalence compared to other mental conditions, it has a negative impact on social and occupational functions. This study aimed to assess the appropriateness of antipsychotic medications administered to schizophrenic patients and describe current treatment patterns for schizophrenia. A retrospective cohort study was conducted in all patients over the age of 15 with an active diagnosis of schizophrenia and treated with antipsychotics between 2008 and 2013 in the Valencia region. A total of 19,718 patients were eligible for inclusion. The main outcome assessed was inappropriateness of the pharmacotherapeutic management, including polypharmacy use. Altogether, 30.4% of patients received antipsychotic polypharmacy, and 6.8% were prescribed three or more antipsychotics. Overdosage affected 318 individuals (1.6%), and 21.5% used concomitant psychotropics without an associated psychiatric diagnosis. Women and people with a comorbid condition like anxiety or depression were less likely to receive antipsychotic polypharmacy. In contrast, increased polypharmacy was associated with concomitant treatment with other psychoactive drugs, and only in user on maintenance therapy, with more visits to the mental health hospital. Overall, we observed a high level of inappropriateness in antipsychotic prescriptions. Greater adherence to guidelines could maximize the benefits of antipsychotic medications while minimizing risk of adverse effects.<\/jats:p>","DOI":"10.1038\/s41598-021-92731-w","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T10:07:24Z","timestamp":1624961244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment patterns and appropriateness of antipsychotic prescriptions in patients with schizophrenia"],"prefix":"10.1038","volume":"11","author":[{"given":"Ver\u00f3nica","family":"Gam\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Hurtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Salazar-Fraile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Sanf\u00e9lix-Gimeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"92731_CR1","unstructured":"World Health Organization (WHO). Schizophrenia. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schizophrenia (2019)."},{"key":"92731_CR2","doi-asserted-by":"publisher","first-page":"15067","DOI":"10.1038\/nrdp.2015.67","volume":"1","author":"R Kahn","year":"2015","unstructured":"Kahn, R. et al. Schizophrenia. Nat. Rev. Dis. Primers. 1, 15067 (2015).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"92731_CR3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/cells9020366","volume":"9","author":"A Hoffmann","year":"2020","unstructured":"Hoffmann, A., Ziller, M. & Spengler, D. Focus on causality in ESC\/iPSC-based modeling of psychiatric disorders. Cells 9, 366 (2020).","journal-title":"Cells"},{"key":"92731_CR4","doi-asserted-by":"publisher","first-page":"144390","DOI":"10.1016\/j.gene.2020.144390","volume":"734","author":"W Fatima","year":"2020","unstructured":"Fatima, W. et al. Chromosomal region 1q241 is associated with increased risk of schizophrenia in Pakistani population. Gene 734, 144390 (2020).","journal-title":"Gene"},{"key":"92731_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2008.04.011","volume":"102","author":"R Tandon","year":"2008","unstructured":"Tandon, R., Keshavan, M. S. & Nasrallah, H. A. Schizophrenia, \u201cjust the facts\u201d what we know in 2008. Schizophr. Res. 102, 1\u201318 (2008).","journal-title":"Schizophr. Res."},{"key":"92731_CR6","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/schbul\/sbs096","volume":"38","author":"E Vassos","year":"2012","unstructured":"Vassos, E., Pedersen, C. B., Murray, R. M., Collier, D. A. & Lewis, C. M. Meta-analysis of the association of urbanicity with schizophrenia. Schizophr Bull. 38, 1118\u20131123 (2012).","journal-title":"Schizophr Bull."},{"key":"92731_CR7","doi-asserted-by":"publisher","first-page":"153940","DOI":"10.1016\/j.metabol.2019.07.004","volume":"100S","author":"E Costa","year":"2019","unstructured":"Costa, E., Silva, J. A. & Steffen, R. E. Urban environment and psychiatric disorders: a review of the neuroscience and biology. Metabolism 100S, 153940 (2019).","journal-title":"Metabolism"},{"key":"92731_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00406-019-01074-1","volume":"270","author":"MA Reinhard","year":"2019","unstructured":"Reinhard, M. A. et al. The vicious circle of social exclusion and psychopathology: A systematic review of experimental ostracism research in psychiatric disorders. Eur. Arch. Psychiatry Clin. Neurosci. 270, 521\u2013532 (2019).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"92731_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/S2045796014000614","volume":"25","author":"B Moreno-K\u00fcstner","year":"2016","unstructured":"Moreno-K\u00fcstner, B. et al. Prevalence of schizophrenia and related disorders in Malaga (Spain): Results using multiple clinical databases. Epidemiol. Psychiatr. Sci. 25, 38\u201348 (2016).","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"92731_CR10","unstructured":"Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: A systematic analysis for the Global Burden of Disease Study 2013.\u00a0Lancet. 386, 743\u2013800 (2015)."},{"key":"92731_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1192\/bjp.bp.109.067512","volume":"196","author":"S Brown","year":"2010","unstructured":"Brown, S., Kim, M., Mitchell, C. & Inskip, H. Twenty-five year mortality of a community cohort with schizophrenia. Br. J Psychiatry. 196, 116\u2013121 (2010).","journal-title":"Br. J Psychiatry."},{"key":"92731_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11126-019-09645-0","volume":"90","author":"MV Seeman","year":"2019","unstructured":"Seeman, M. V. Schizophrenia mortality: Barriers to progress. Psychiatr. Q. 90, 553\u2013563 (2019).","journal-title":"Psychiatr. Q."},{"key":"92731_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/wps.20040","volume":"12","author":"G Gerlinger","year":"2013","unstructured":"Gerlinger, G. et al. Personal stigma in schizophrenia spectrum disorders: A systematic review of prevalence rates, correlates, impact and interventions. World Psychiatry 12, 155\u2013164 (2013).","journal-title":"World Psychiatry"},{"key":"92731_CR14","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3389\/fpsyt.2019.00803","volume":"10","author":"EG Kornetova","year":"2019","unstructured":"Kornetova, E. G. et al. Changes in body fat and related biochemical parameters associated with atypical antipsychotic drug treatment in schizophrenia patients with or without metabolic syndrome. Front Psychiatry. 10, 803 (2019).","journal-title":"Front Psychiatry."},{"key":"92731_CR15","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1176\/appi.focus.18307","volume":"18","author":"S Ijaz","year":"2020","unstructured":"Ijaz, S. et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: A review of systematic reviews. Focus 18, 482\u2013492 (2020).","journal-title":"Focus"},{"key":"92731_CR16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S2215-0366(16)00085-7","volume":"3","author":"G Gr\u00fcnder","year":"2016","unstructured":"Gr\u00fcnder, G. et al. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: A double-blind, randomised study. Lancet Psychiatry 3, 717\u2013729 (2016).","journal-title":"Lancet Psychiatry"},{"key":"92731_CR17","unstructured":"NICE, National Institute for Health and Clinical Excellence. Psycosis and Schizophrenia in adults. The NICE Guideline on treatment and management (2014)."},{"key":"92731_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881119889296","volume":"34","author":"TR Barnes","year":"2020","unstructured":"Barnes, T. R. et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 34, 3\u201378 (2020).","journal-title":"J. Psychopharmacol."},{"key":"92731_CR19","doi-asserted-by":"crossref","unstructured":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. (2019).","DOI":"10.1176\/appi.books.9780890424841"},{"key":"92731_CR20","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/ije\/dyz266","volume":"49","author":"A Garc\u00eda-Sempere","year":"2020","unstructured":"Garc\u00eda-Sempere, A. et al. Data resource profile: The Valencia health system integrated database (VID). Int. J. Epidemiol. 49, 740\u2013741 (2020).","journal-title":"Int. J. Epidemiol."},{"key":"92731_CR21","unstructured":"Servicio Andaluz de Salud. Gu\u00eda Pr\u00e1ctica para el Tratamiento de la Psicosis y Esquizofrenia. Manejo en Atenci\u00f3n Primaria y en Salud Mental. Consejer\u00eda de Salud y Familias. Junta de Andaluc\u00eda (2019)"},{"key":"92731_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/0706743717720448","volume":"62","author":"G Remington","year":"2017","unstructured":"Remington, G. et al. Guidelines for the pharmacotherapy of schizophrenia in adults. Can. J. Psychiatry. 62, 604\u2013616 (2017).","journal-title":"Can. J. Psychiatry."},{"key":"92731_CR23","unstructured":"Grupo de trabajo de la Gu\u00eda de Pr\u00e1ctica Cl\u00ednica sobre la Esquizofrenia y el Trastorno Psic\u00f3tico Incipiente. F\u00f2rum de Salut Mental, coordinaci\u00f3n. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica sobre la Esquizofrenia y el Trastorno Psic\u00f3tico Incipiente. Madrid: Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad y Consumo. Ag\u00e8ncia d\u2019Avaluaci\u00f3 de Tecnologia i Recerca M\u00e8diques; Gu\u00eda de Pr\u00e1ctica Cl\u00ednica: AATRM. N\u00ba 2006\/05-2 (2009)."},{"key":"92731_CR24","unstructured":"Subdirecci\u00f3n de Salud Mental, Servicio Murciano de Salud. Gu\u00eda Pr\u00e1ctica Cl\u00ednica para el Tratamiento de la Esquizofrenia en Centros de Salud Mental (2009)."},{"key":"92731_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/schbul\/sbp130","volume":"36","author":"J Kreyenbuhl","year":"2009","unstructured":"Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B. & Dixon, L. B. Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2009. Schizophr. Bull. 36, 94\u2013103 (2009).","journal-title":"Schizophr. Bull."},{"key":"92731_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-244X-12-42","volume":"12","author":"M Bernardo","year":"2012","unstructured":"Bernardo, M. et al. Antipsychotic polypharmacy in a regional health service: A population-based study. BMC Psychiatry 12, 42 (2012).","journal-title":"BMC Psychiatry"},{"key":"92731_CR27","first-page":"164","volume":"41","author":"BA Moore","year":"2017","unstructured":"Moore, B. A., Morrissette, D. A., Meyer, J. M. & Stahl, S. M. Drug information update: Unconventional treatment strategies for schizophrenia: Polypharmacy and heroic dosing. Psychol. Bull. 41, 164\u2013168 (2017).","journal-title":"Psychol. Bull."},{"key":"92731_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/wps.20387","volume":"16","author":"B Galling","year":"2017","unstructured":"Galling, B. et al. Antipsychotic augmentation vs monotherapy in schizophrenia: Systematic review, meta-analysis and meta-regression analysis. World Psychiatry 16, 77\u201389 (2017).","journal-title":"World Psychiatry"},{"key":"92731_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bcpt.13384","volume":"126","author":"L Baandrup","year":"2020","unstructured":"Baandrup, L. Polypharmacy in schizophrenia. Basic Clin. Pharmacol. Toxicol. 126, 183\u2013192 (2020).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"92731_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4068\/cmj.2020.56.3.157","volume":"56","author":"CU Pae","year":"2020","unstructured":"Pae, C. U. Antipsychotic polypharmacy in treatment of schizophrenia; should or should not?. Chonnam Med. J. 56, 157\u2013165 (2020).","journal-title":"Chonnam Med. J."},{"key":"92731_CR31","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.3390\/ijms18102174","volume":"18","author":"SW Jeon","year":"2017","unstructured":"Jeon, S. W. & Kim, Y. K. unresolved issues for utilization of atypical antipsychotics in schizophrenia: Antipsychotic polypharmacy and metabolic syndrome. Int. J. Mol. Sci. 18, 2174 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"92731_CR32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00127-012-0586-6","volume":"48","author":"JT Suokas","year":"2013","unstructured":"Suokas, J. T., Suvisaari, J. M., Haukka, J., Korhonen, P. & Tiihonen, J. Description of long-term polypharmacy among schizophrenia outpatients. Soc. Psychiatry Psychiatr. Epidemiol. 48, 631\u2013638 (2013).","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"92731_CR33","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1007\/s11096-019-00930-3","volume":"41","author":"ML Nguyen","year":"2019","unstructured":"Nguyen, M. L., Sunderland, B., Lim, S., Hattingh, L. & Chalmers, L. The hidden magnitude of polypharmacy: Using defined daily doses and maximum licensed daily doses to measure antipsychotic load. Int. J. Clin. Pharm. 41, 1642\u20131651 (2019).","journal-title":"Int. J. Clin. Pharm."},{"key":"92731_CR34","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","volume":"76","author":"J Tiihonen","year":"2019","unstructured":"Tiihonen, J. et al. Association of antipsychotic polypharmacy vs. monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiat. 76, 499\u2013507 (2019).","journal-title":"JAMA Psychiat."},{"key":"92731_CR35","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/schbul\/sbn018","volume":"35","author":"CU Correll","year":"2009","unstructured":"Correll, C. U., Rummel-Kluge, C., Corves, C., Kane, J. M. & Leucht, S. Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophr. Bull. 35, 443\u2013457 (2009).","journal-title":"Schizophr. Bull."},{"issue":"5","key":"92731_CR36","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jemermed.2012.03.002","volume":"43","author":"AB Minns","year":"2012","unstructured":"Minns, A. B. & Clark, R. F. Toxicology and overdose of atypical antipsychotics. J. Emerg. Med. 43(5), 906\u2013913 (2012).","journal-title":"J. Emerg. Med."},{"key":"#cr-split#-92731_CR37.1","doi-asserted-by":"crossref","unstructured":"Levine, M. & Ruha, A. M. Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management [published correction appears in CNS Drugs. 2012","DOI":"10.2165\/11631640-000000000-00000"},{"key":"#cr-split#-92731_CR37.2","doi-asserted-by":"crossref","unstructured":"26(9):812]. CNS Drugs. 26, 601\u2010611 (2012).","DOI":"10.2165\/11631640-000000000-00000"},{"key":"92731_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1081\/CLT-100102873","volume":"39","author":"MJ Burns","year":"2001","unstructured":"Burns, M. J. The pharmacology and toxicology of atypical antipsychotic agents. J. Toxicol. Clin. Toxicol. 39, 1\u201314 (2001).","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"92731_CR39","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.euroneuro.2013.04.010","volume":"23","author":"O Agid","year":"2013","unstructured":"Agid, O. et al. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. Eur. Neuropsychopharmacol. 23, 1017\u20131022 (2013).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"92731_CR40","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1177\/0269881108100777","volume":"24","author":"D Elie","year":"2010","unstructured":"Elie, D. et al. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol. 24, 1037\u20131044 (2010).","journal-title":"J Psychopharmacol."},{"key":"#cr-split#-92731_CR41.1","unstructured":"Torniainen, M. et al. Antipsychotic treatment and mortality in schizophrenia [published correction appears in Schizophr Bull. 2016"},{"key":"#cr-split#-92731_CR41.2","doi-asserted-by":"crossref","unstructured":"42(2):528]. Schizophr Bull. 41, 656\u2010663 (2015).","DOI":"10.1093\/schbul\/sbu164"},{"key":"92731_CR42","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00228-019-02654-9","volume":"75","author":"J Sultana","year":"2019","unstructured":"Sultana, J. et al. Antipsychotic utilization patterns among patients with schizophrenic disorder: A cross-national analysis in four countries. Eur J Clin Pharmacol. 75, 1005\u20131015 (2019).","journal-title":"Eur J Clin Pharmacol."},{"key":"92731_CR43","doi-asserted-by":"publisher","first-page":"112660","DOI":"10.1016\/j.psychres.2019.112660","volume":"284","author":"JI de la Iglesia-Larrad","year":"2020","unstructured":"de la Iglesia-Larrad, J. I. et al. Benzodiazepine abuse, misuse, dependence, and withdrawal among schizophrenic patients: A review of the literature. Psychiatry Res. 284, 112660 (2020).","journal-title":"Psychiatry Res."},{"key":"92731_CR44","first-page":"240","volume":"43","author":"R Upthegrove","year":"2017","unstructured":"Upthegrove, R., Marwaha, S. & Birchwood, M. Depression and schizophrenia: cause, consequence, or trans-diagnostic issue?. Schizophr. Bull. 43, 240\u2013244 (2017).","journal-title":"Schizophr. Bull."},{"issue":"3","key":"92731_CR45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bcpt.13384","volume":"126","author":"L Baandrup","year":"2020","unstructured":"Baandrup, L. Polypharmacy in schizophrenia. Basic Clin. Pharmacol Toxicol. 126(3), 183\u2013192. https:\/\/doi.org\/10.1111\/bcpt.13384 (2020) (Epub 2020 Jan 15).","journal-title":"Basic Clin. Pharmacol Toxicol."},{"key":"92731_CR46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/schbul\/sbq042","volume":"38","author":"C Rummel-Kluge","year":"2012","unstructured":"Rummel-Kluge, C. et al. Second-generation antipsychotic drugs and extrapyramidal side effects: A systematic review and meta-analysis of head-to-head comparisons. Schizophr. Bull. 38, 167\u2013177 (2012).","journal-title":"Schizophr. Bull."},{"key":"92731_CR47","doi-asserted-by":"crossref","unstructured":"Huhn, M. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis [published correction appears in Lancet. 2019 Sep 14;394(10202):918].\u00a0Lancet. 394, 939\u2013951 (2019).","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"92731_CR48","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jemermed.2017.10.011","volume":"54","author":"LS Zun","year":"2018","unstructured":"Zun, L. S. Evidence-based review of pharmacotherapy for acute agitation. Part 1: onset of efficacy. J. Emerg. Med. 54, 364\u2013374 (2018).","journal-title":"J. Emerg. Med."},{"key":"92731_CR49","doi-asserted-by":"publisher","first-page":"e0139403","DOI":"10.1371\/journal.pone.0139403","volume":"10","author":"AM Gaviria","year":"2015","unstructured":"Gaviria, A. M. et al. A non-interventional naturalistic study of the prescription patterns of antipsychotics in patients with schizophrenia from the Spanish Province of Tarragona. PLoS ONE 10, e0139403 (2015).","journal-title":"PLoS ONE"},{"key":"92731_CR50","doi-asserted-by":"publisher","first-page":"12123","DOI":"10.4088\/JCP.18com12123","volume":"80","author":"JM Kane","year":"2019","unstructured":"Kane, J. M. et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J. Clin. Psychiatry. 80, 12123 (2019).","journal-title":"J. Clin. Psychiatry."},{"key":"92731_CR51","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/schbul\/sbx007","volume":"43","author":"T Wimberley","year":"2017","unstructured":"Wimberley, T. et al. Polygenic risk score for schizophrenia and treatment-resistant schizophrenia. Schizophr. Bull. 43, 1064\u20131069 (2017).","journal-title":"Schizophr. Bull."},{"key":"92731_CR52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.rpsm.2018.02.005","volume":"12","author":"FJ Sanz-Fuentenebro","year":"2019","unstructured":"Sanz-Fuentenebro, F. J., Uriarte, J. J. U., Bonet, P., Molina, V. & Bernardo, M. Pattern of use of clozapine in Spain: Variability and under-prescription. Rev. Psiquiatr. Salud. Ment. 12, 151\u2013162 (2019).","journal-title":"Rev. Psiquiatr. Salud. Ment."},{"key":"92731_CR53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/acps.13111","volume":"141","author":"JM Rubio","year":"2020","unstructured":"Rubio, J. M. & Kane, J. M. How and when to use clozapine. Acta Psychiatr. Scand. 141, 178\u2013189 (2020).","journal-title":"Acta Psychiatr. Scand."}],"updated-by":[{"DOI":"10.1038\/s41598-024-55913-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92731-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92731-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92731-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:10:13Z","timestamp":1709338213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92731-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["92731"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-92731-w","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-024-55913-w","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-024-55913-w","URL":"https:\/\/doi.org\/10.1038\/s41598-024-55913-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13509"}}